Related Experiment Video
Updated: Apr 11, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
New small molecules targeting apoptosis and cell viability in osteosarcoma
Doris Maugg1, Ina Rothenaigner2, Kenji Schorpp2
1Clinical Cooperation Group Osteosarcoma, Institute of Radiation Biology, Helmholtz Zentrum München-National Research Centre for Environmental Health, Neuherberg, Germany; Department of Pediatrics and Children´s Cancer Research Center, Technische Universität München, Munich, Germany.
Abstract:
Despite the option of multimodal therapy in the treatment strategies of osteosarcoma (OS), the most common primary malignant bone tumor, the standard therapy has not changed over the last decades and still involves multidrug chemotherapy and radical surgery. Although successfully applied in many patients a large number of patients eventually develop recurrent or metastatic disease in which current therapeutic regimens often lack efficacy. Thus, new therapeutic strategies are urgently needed. In this study, we performed a phenotypic high-throughput screening campaign using a 25,000 small-molecule diversity library to identify new small molecules selectively targeting osteosarcoma cells. We could identify two new small molecules that specifically reduced cell viability in OS cell lines U2OS and HOS, but affected neither hepatocellular carcinoma cell line (HepG2) nor primary human osteoblasts (hOB). In addition, the two compounds induced caspase 3 and 7 activity in the U2OS cell line. Compared to conventional drugs generally used in OS treatment such as doxorubicin, we indeed observed a greater sensitivity of OS cell viability to the newly identified compounds compared to doxorubicin and staurosporine. The p53-negative OS cell line Saos-2 almost completely lacked sensitivity to compound treatment that could indicate a role of p53 in the drug response. Taken together, our data show potential implications for designing more efficient therapies in OS.
Insights
Researchers screened 25,000 small molecules to find new osteosarcoma (OS) treatments. Two compounds effectively reduced OS cell viability, showing promise for more effective therapies against this bone cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Osteosarcoma (OS) is the most common primary malignant bone tumor.
- Current standard treatments (chemotherapy, surgery) have limited efficacy in recurrent or metastatic disease.
- Novel therapeutic strategies are urgently needed for osteosarcoma.
Purpose of the Study:
- To identify novel small molecules selectively targeting osteosarcoma cells.
- To evaluate the efficacy of identified compounds in preclinical models.
- To explore potential mechanisms of action, including the role of p53.
Main Methods:
- Phenotypic high-throughput screening of a 25,000 small-molecule library.
- Assessing cell viability in osteosarcoma cell lines (U2OS, HOS, Saos-2), a liver cancer cell line (HepG2), and primary human osteoblasts (hOB).
- Measuring caspase 3 and 7 activity and comparing compound sensitivity to doxorubicin and staurosporine.
Main Results:
- Two novel small molecules were identified that selectively reduced osteosarcoma cell viability.
- These compounds did not affect hepatocellular carcinoma cells or primary osteoblasts.
- The identified molecules induced caspase 3 and 7 activity and showed greater efficacy than doxorubicin in OS cells.
- Sensitivity to compounds was reduced in p53-negative osteosarcoma cells, suggesting a role for p53.
Conclusions:
- The identified small molecules demonstrate selective cytotoxicity against osteosarcoma cells.
- These compounds represent promising candidates for developing more effective osteosarcoma therapies.
- Further investigation into the p53 pathway may inform future drug development for osteosarcoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31The Intrinsic Apoptotic Pathway
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...